Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYMPHONY HD-naive: Enarodustat in ESA-naive anemic CKD patients on hemodialysis
jRCT2080223646Phase 3Completed
- Sponsor
- Japan Tobacco
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of enarodustat in anaemia and chronic kidney disease (CKD), sponsored by Japan Tobacco. Primary endpoints: Hemoglobin response over initial 4 weeks and Safety over 24 weeks. Started Sep 2017; status: completed.
02
Drugs
enarodustat
03
Conditions
anaemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2080223646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223646.